Key result
Acute phase proteins like CRP and Pentraxin 3 track inflammation and prognosis in ACS.
Why the study?
The role and implications of increased plasma concentrations of acute phase proteins other than CRP in patients with ACS are still not completely defined.
Answers are grounded in this paper and cite their sources.
This review outlines the current understanding of various acute phase proteins as prognostic inflammatory markers in acute coronary syndrome.
Inflammation is essential for atherogenesis, and many inflammatory markers have been analyzed for their association with short- and long-term outcome in patients with manifestations of coronary artery disease. C-reactive protein (CRP) plasma levels increase in patients with acute coronary syndrome (ACS). CPR is an important prognostic marker in ACS. Although CRP will remain over time a useful marker, the role and implications of increased plasma concentrations of other acute phase proteins (APPs), such as alpha-1-antitrypsin (A1AT), alpha-1 glycoprotein (A1GP), haptoglobin (HG), ceruloplasmin (CP), and C3c and C4 complement fraction, in patients with ACS are still not completely defined. Controversy is the role of statins and other drugs on inflammatory markers. This review summarizes the experimental and clinical evidence regarding the role, and the biological and clinical significance of these APPs in ACS. Furthermore, biological and clinical significance of Pentraxin 3 (PTX3), a member of the pentraxin superfamily, are discussesed.
No takes yet. Share an insight, caveat, or question.
Correale et al. (2012) conducted a review in Acute Coronary Syndrome. Acute phase proteins was evaluated. Acute phase proteins, including C-reactive protein and Pentraxin 3, serve as important inflammatory and prognostic markers in patients with acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: